Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum

31 Jan 2023

Abstract excerpt

Three pathologic processes are characteristic of Alzheimer disease (AD): β-amyloid, hyperphosphorylated tau, and neurodegeneration. Our understanding of AD is undergoing a transformation due to our ability to measure biomarkers of these processes across different stages of cognitive impairment. There is growing interest in using AD biomarker tests in care and research and, with this, a growing need for guidance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dementia and Cognitive Impairment Research
Share to Ethics in Clinical Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 36720642
DOI: 10.1212/wnl.0000000000206891

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease ContinuumPMID 36720642Read ↗

Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research contextSemantic proximity Read ↗

Considerations regarding a diagnosis of Alzheimer’s Disease before dementia: a systematic reviewSemantic proximity Read ↗

Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies (WeSHARE)Semantic proximity Read ↗

‘That would be dreadful’: The ethical, legal, and social challenges of sharing your Alzheimer’s disease biomarker and genetic testing results with othersSemantic proximity Read ↗

A Multidisciplinary Perspective on Research Participation in the Era of Post-Amyloid Disclosure and Disease-Modifying TherapiesSemantic proximity Read ↗

Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics.Semantic proximity Read ↗

Recommendations for genetic counseling for individuals at risk of autosomal dominant Alzheimer's disease in Latin America.Semantic proximity Read ↗

Safety and Tolerability of APOE Genotyping and Disclosure in Cognitively Normal Volunteers From the Butler Alzheimer's Prevention Registry.Semantic proximity Read ↗

Genetic testing for neurodegenerative diseases: Ethical and health communication challenges.Semantic proximity Read ↗

Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.Semantic proximity Read ↗

Disclosing Genetic Risk of Alzheimer's Disease to Cognitively Unimpaired Older Adults: Findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II).Semantic proximity Read ↗

Public perceptions of presymptomatic testing for Alzheimer disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.